Methylphenidate in Tardive Dyskinesia
Abstract
Methylphenidate, an amphetamine-like central nervous system (CNS) stimulant used successfully in reversing acute neuroleptic-induced neurological symptoms, was given in a placebo-controlled study to 17 patients with tardive dyskinesia. On global ratings three subjects were improved, six showed an increase in symptoms, and eight showed no changes. The authors conclude that methylphenidate is not effective in tardive dyskinesia and that the results of this study are in keeping with present knowledge about CNS pharmacology.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).